Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 Nov;101(3):605–614. doi: 10.1111/j.1476-5381.1990.tb14128.x

Haemodynamic profile of the potassium channel activator EMD 52692 in anaesthetized pigs.

L M Sassen 1, D J Duncker 1, B C Gho 1, H W Diekmann 1, P D Verdouw 1
PMCID: PMC1917749  PMID: 2076480

Abstract

1. The systemic and regional haemodynamic effects of the potassium channel activator EMD 52692 or its solvent were investigated after intravenous and after intracoronary administration in anaesthetized pigs. 2. Consecutive intravenous 10 min infusions of EMD 52692 (0.15, 0.30, 0.60, 1.20 micrograms kg-1 min-1; n = 7) dose-dependently decreased mean arterial blood pressure by up to 50%. This was entirely due to peripheral vasodilatation, since cardiac output did not change. Heart rate increased by up to 50%, while left ventricular end diastolic pressure decreased dose-dependently from 6 +/- 1 mmHg to 3 +/- 1 mmHg (P less than 0.05), and stroke volume decreased from 30 +/- 2 ml to 21 +/- 2 ml (P less than 0.05). Left ventricular dP/dtmax was not affected. 3. Although cardiac output did not change, EMD 52692 caused a redistribution of blood flow from the arteriovenous anastomoses to the capillary channels. Blood flow to the adrenals, small intestine, stomach, bladder, spleen and brain increased, while renal blood flow decreased and blood flow to several muscle groups and skin were not altered. Vascular conductance was increased dose-dependently in all organs, except for the kidneys, where after the initial increase, vascular conductance returned to baseline with the highest dose. Particularly striking were the effects on the vasculature of the brain. With the highest dose of EMD 52692 blood flow more than doubled, while vascular conductance increased four fold. 4. Transmural myocardial blood flow increased slightly, which was entirely due to an increase in subepicardial blood flow. Myocardial O2-consumption and segment length shortening were not significantly affected. 5. After consecutive 10 min intracoronary infusions (0.0095, 0.019, 0.0375 and 0.075 microgram kg-1 min-1; n = 7) into the left anterior descending coronary artery (LADCA), mean arterial blood pressure was maintained with the lowest two doses, but decreased by up to 15% with the higher doses, whereas heart rate increased by up to 24%. Blood flow to the LADCA-perfused myocardium doubled with the highest dose, the subepicardium benefitting the most. Coronary venous O2-saturation increased dose-dependently from 23 +/- 2% to 60 +/- 4%, while myocardial O2-consumption of the LADCA-perfused myocardium was not affected by the drug. 6. It is concluded that EMD 52692 is a potent vasodilator, with particularly pronounced effects on vasculature of the brain.(ABSTRACT TRUNCATED AT 400 WORDS)

Full text

PDF
605

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arrigoni-Martelli E., Nielsen C. K., Olsen U. B., Petersen H. J. N''-cyano-N-4-pyridyl-N'-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): a new, potent vasodilator. Experientia. 1980 Apr 15;36(4):445–447. doi: 10.1007/BF01975139. [DOI] [PubMed] [Google Scholar]
  2. Baile E. M., Nelems J. M., Schulzer M., Paré P. D. Measurement of regional bronchial arterial blood flow and bronchovascular resistance in dogs. J Appl Physiol Respir Environ Exerc Physiol. 1982 Oct;53(4):1044–1049. doi: 10.1152/jappl.1982.53.4.1044. [DOI] [PubMed] [Google Scholar]
  3. Bolton T. B. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev. 1979 Jul;59(3):606–718. doi: 10.1152/physrev.1979.59.3.606. [DOI] [PubMed] [Google Scholar]
  4. Bray K. M., Newgreen D. T., Small R. C., Southerton J. S., Taylor S. G., Weir S. W., Weston A. H. Evidence that the mechanism of the inhibitory action of pinacidil in rat and guinea-pig smooth muscle differs from that of glyceryl trinitrate. Br J Pharmacol. 1987 Jun;91(2):421–429. doi: 10.1111/j.1476-5381.1987.tb10297.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buckingham R. E., Clapham J. C., Hamilton T. C., Longman S. D., Norton J., Poyser R. H. BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol. 1986 Jul-Aug;8(4):798–804. doi: 10.1097/00005344-198709010-00022. [DOI] [PubMed] [Google Scholar]
  6. Carriére S. Factors affecting renal cortical blood flow. A review. Can J Physiol Pharmacol. 1975 Feb;53(1):1–20. [PubMed] [Google Scholar]
  7. Clapham J. C., Wilson C. Anti-spasmogenic and spasmolytic effects of BRL 34915: a comparison with nifedipine and nicorandil. J Auton Pharmacol. 1987 Sep;7(3):233–242. doi: 10.1111/j.1474-8673.1987.tb00152.x. [DOI] [PubMed] [Google Scholar]
  8. Cook N. S. Effect of some potassium channel blockers on contractile responses of the rabbit aorta. J Cardiovasc Pharmacol. 1989 Feb;13(2):299–306. doi: 10.1097/00005344-198902000-00019. [DOI] [PubMed] [Google Scholar]
  9. Cook N. S., Hof R. P. Cardiovascular effects of apamin and BRL 34915 in rats and rabbits. Br J Pharmacol. 1988 Jan;93(1):121–131. doi: 10.1111/j.1476-5381.1988.tb11412.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cook N. S. The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol Sci. 1988 Jan;9(1):21–28. doi: 10.1016/0165-6147(88)90238-6. [DOI] [PubMed] [Google Scholar]
  11. Daut J., Maier-Rudolph W., von Beckerath N., Mehrke G., Günther K., Goedel-Meinen L. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science. 1990 Mar 16;247(4948):1341–1344. doi: 10.1126/science.2107575. [DOI] [PubMed] [Google Scholar]
  12. De Peyer J. E., Lues I., Gericke R., Häusler G. Characterization of a novel K+ channel activator, EMD 52962, in electrophysiological and pharmacological experiments. Pflugers Arch. 1989;414 (Suppl 1):S191–S191. doi: 10.1007/BF00582301. [DOI] [PubMed] [Google Scholar]
  13. Domenech R. J., Goich J. Effect of heart rate on regional coronary blood flow. Cardiovasc Res. 1976 Mar;10(2):224–231. doi: 10.1093/cvr/10.2.224. [DOI] [PubMed] [Google Scholar]
  14. Duncker D. J., Hartog J. M., Hugenholtz P. G., Saxena P. R., Verdouw P. D. The effects of nisoldipine (Bay K 5552) on cardiovascular performance and regional blood flow in pentobarbital-anaesthetized pigs with or without beta-adrenoceptor blockade. Br J Pharmacol. 1986 May;88(1):9–18. doi: 10.1111/j.1476-5381.1986.tb09465.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Duncker D. J., Saxena P. R., Verdouw P. D. Systemic haemodynamics of dihydropyridine derivatives in conscious pigs with or without propranolol. Eur J Pharmacol. 1988 Nov 8;156(3):401–409. doi: 10.1016/0014-2999(88)90286-5. [DOI] [PubMed] [Google Scholar]
  16. Findlay I., Deroubaix E., Guiraudou P., Coraboeuf E. Effects of activation of ATP-sensitive K+ channels in mammalian ventricular myocytes. Am J Physiol. 1989 Nov;257(5 Pt 2):H1551–H1559. doi: 10.1152/ajpheart.1989.257.5.H1551. [DOI] [PubMed] [Google Scholar]
  17. Freeman G. L., LeWinter M. M., Engler R. L., Covell J. W. Relationship between myocardial fiber direction and segment shortening in the midwall of the canine left ventricle. Circ Res. 1985 Jan;56(1):31–39. doi: 10.1161/01.res.56.1.31. [DOI] [PubMed] [Google Scholar]
  18. Gotanda K., Satoh K., Taira N. Is the cardiovascular profile of BRL 34915 characteristic of potassium channel activators? J Cardiovasc Pharmacol. 1988 Aug;12(2):239–246. doi: 10.1097/00005344-198808000-00015. [DOI] [PubMed] [Google Scholar]
  19. Hamilton T. C., Weir S. W., Weston A. H. Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol. 1986 May;88(1):103–111. doi: 10.1111/j.1476-5381.1986.tb09476.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hof R. P., Hof A. Differential effects of antihypertensive drugs on nutritive and nonnutritive blood flow in anaesthetized rabbits. J Cardiovasc Pharmacol. 1989 Apr;13(4):565–571. [PubMed] [Google Scholar]
  21. Kaihara S., Van Heerden P. D., Migita T., Wagner H. N., Jr Measure- ment of distribution of cardiac output. J Appl Physiol. 1968 Dec;25(6):696–700. doi: 10.1152/jappl.1968.25.6.696. [DOI] [PubMed] [Google Scholar]
  22. Longman S. D., Clapham J. C., Wilson C., Hamilton T. C. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil. J Cardiovasc Pharmacol. 1988;12(5):535–542. [PubMed] [Google Scholar]
  23. Sassen L. M., Soei L. K., Koning M. M., Verdouw P. D. The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs. Br J Pharmacol. 1990 Feb;99(2):355–363. doi: 10.1111/j.1476-5381.1990.tb14708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Saxena P. R., Schamhardt H. C., Forsyth R. P., Hoeve J. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed. 1980 Dec;12(2-3):63–84. doi: 10.1016/0010-468x(80)90053-7. [DOI] [PubMed] [Google Scholar]
  25. Saxena P. R., Verdouw P. D. Tissue blood flow and localization of arteriovenous anastomoses in pigs with microspheres of four different sizes. Pflugers Arch. 1985 Feb;403(2):128–135. doi: 10.1007/BF00584089. [DOI] [PubMed] [Google Scholar]
  26. Verdouw P. D., Sassen L. M., Duncker D. J., Schmeets I. O., Rensen R. J., Saxena P. R. Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs. Naunyn Schmiedebergs Arch Pharmacol. 1987 Sep;336(3):352–358. doi: 10.1007/BF00172690. [DOI] [PubMed] [Google Scholar]
  27. Webb D. J., Benjamin N., Vallance P. The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers. Br J Clin Pharmacol. 1989 Jun;27(6):757–761. doi: 10.1111/j.1365-2125.1989.tb03437.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Weir S. W., Weston A. H. The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels. Br J Pharmacol. 1986 May;88(1):121–128. doi: 10.1111/j.1476-5381.1986.tb09478.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wright F. S., Briggs J. P. Feedback control of glomerular blood flow, pressure, and filtration rate. Physiol Rev. 1979 Oct;59(4):958–1006. doi: 10.1152/physrev.1979.59.4.958. [DOI] [PubMed] [Google Scholar]
  30. Yanagisawa T., Hashimoto H., Taira N. The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle. Br J Pharmacol. 1988 Oct;95(2):393–398. doi: 10.1111/j.1476-5381.1988.tb11658.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES